- Home
- CATX vs ACRS Comparison
CATX vs ACRS Comparison
Compare CATX & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATX
- ACRS
- Stock Information
- Founded
- CATX 1983
- ACRS 2012
- Country
- CATX United States
- ACRS United States
- Employees
- CATX N/A
- ACRS N/A
- Industry
- CATX Medical/Dental Instruments
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- CATX Health Care
- ACRS Health Care
- Exchange
- CATX Nasdaq
- ACRS Nasdaq
- Market Cap
- CATX 239.0M
- ACRS 198.2M
- IPO Year
- CATX N/A
- ACRS 2015
- Fundamental
- Price
- CATX $2.73
- ACRS $2.52
- Analyst Decision
- CATX Strong Buy
- ACRS Strong Buy
- Analyst Count
- CATX 10
- ACRS 9
- Target Price
- CATX $12.30
- ACRS $9.25
- AVG Volume (30 Days)
- CATX 1.7M
- ACRS 1.3M
- Earning Date
- CATX 11-10-2025
- ACRS 11-06-2025
- Dividend Yield
- CATX N/A
- ACRS N/A
- EPS Growth
- CATX N/A
- ACRS N/A
- EPS
- CATX N/A
- ACRS N/A
- Revenue
- CATX $1,235,000.00
- ACRS $16,789,000.00
- Revenue This Year
- CATX N/A
- ACRS N/A
- Revenue Next Year
- CATX N/A
- ACRS N/A
- P/E Ratio
- CATX N/A
- ACRS N/A
- Revenue Growth
- CATX N/A
- ACRS N/A
- 52 Week Low
- CATX $1.60
- ACRS $1.05
- 52 Week High
- CATX $12.90
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- CATX 36.42
- ACRS 67.33
- Support Level
- CATX $2.60
- ACRS $2.24
- Resistance Level
- CATX $3.15
- ACRS $2.47
- Average True Range (ATR)
- CATX 0.36
- ACRS 0.21
- MACD
- CATX -0.15
- ACRS 0.04
- Stochastic Oscillator
- CATX 5.12
- ACRS 88.64
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.